|May 24, 2017
Contact: Whitney Ray
Phone: (850) 245-0150
|en Español||Print Version||Tweet|
Tallahassee, Fla.—Attorney General Pam Bondi and 40 other state attorneys general reached settlement agreements with two former executives of a New Jersey-based generic pharmaceutical manufacturer. The settlement follows an investigation into widespread anticompetitive activity in the generic drug industry leading to higher drug prices for consumers and state governments.
Jason Malek, former president of Heritage Pharmaceuticals, Inc., and Jeffrey Glazer, former chairman and chief executive officer of Heritage Pharmaceuticals, agree to cooperate in the states' ongoing litigation and investigation. As part of this cooperation, Glazer and Malek, both from New Jersey, will provide depositions, documents, information, testimony and other evidence to support the investigation.
These settlements are part of an ongoing investigation into generic drugs, generic drug companies and key executives for suspicious price increases of certain generic pharmaceuticals. The states’ efforts already resulted in a lawsuit against six generic drug makers that alleges a well-coordinated and long-running conspiracy to fix prices and allocate markets for an antibiotic and an oral diabetes medication. This multistate litigation is currently pending in the U.S. District Court for the District of Connecticut and includes Heritage Pharmaceuticals as a defendant.
Following charges of two counts of criminal violations of the Sherman Antitrust Act, Glazer and Malek each entered plea agreements with the U.S. Department of Justice. In addition to the former executives’ cooperation with the multistate investigation, Glazer and Malek will each pay a $25,000 civil penalty to the states.
To view the settlement with Glazer, click here.
To view the settlement with Malek, click here.
For more information on the pending multistate action, click here.